Agency Forms Undergoing Paperwork Reduction Act Review, 68074-68075 [2013-27083]
Download as PDF
<![CDATA[
68074
Federal Register / Vol. 78, No. 219 / Wednesday, November 13, 2013 / Notices
Written comments will be
accepted until 5:00 p.m. ET on
December 4, 2013.
ADDRESSES: Written comments will be
accepted via an online public comment
database at https://healthypeople.gov/
2020/about/publicComment.aspx; by
mail at Office of Disease Prevention and
Health Promotion, U.S. Department of
Health and Human Services, Attn:
Public Comment, 1101 Wootton
Parkway, Room LL–100, Rockville, MD
20852; by fax to 240–453–8281; or by
email to HP2020@hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Theresa Devine, MPH, Office of Disease
Prevention and Health Promotion, U.S.
Department of Health and Human
Services, 1101 Wootton Parkway, Room
LL–100, Rockville, MD 20852,
Theresa.Devine@hhs.gov (email), 240–
453–6112 (telephone), 240–453–8281
(fax).
SUPPLEMENTARY INFORMATION: For three
decades, Healthy People has provided a
comprehensive set of national 10-year
health promotion and disease
prevention objectives aimed at
improving the health of all Americans.
Healthy People 2020 objectives provide
a framework by presenting a
comprehensive picture of the nation’s
health at the beginning of the decade,
establishing national goals and targets to
be achieved by the year 2020, and
monitoring progress over time. The U.S.
Department of Health and Human
Services (HHS) is soliciting the
submission of written comments
regarding new objectives proposed to be
added to Healthy People 2020 since the
fall 2012 public comment period.
Healthy People 2020 is the product of
an extensive collaborative process that
relies on input from a diverse array of
individuals and organizations, both
within and outside the federal
government, with a common interest in
improving the nation’s health. Public
comments were a cornerstone of
Healthy People 2020’s development.
During the first phase of planning for
Healthy People 2020, HHS asked for the
public’s comments on the vision,
mission, and implementation of Healthy
People 2020. Those comments helped
set the framework for Healthy People
2020. The public was also invited to
submit comments on proposed Healthy
People 2020 objectives, which helped
shape the final set of Healthy People
2020 objectives.
The public is now invited to comment
on new objectives proposed to be added
to Healthy People 2020. These new
objectives were developed by Topic
Area workgroups led by various
agencies within the federal government.
sroberts on DSK5SPTVN1PROD with NOTICES
DATES:
VerDate Mar<15>2010
17:14 Nov 12, 2013
Jkt 232001
They have been reviewed by the Federal
Interagency Workgroup on Healthy
People 2020 and are presented now for
the public’s review and comment. The
public is also invited to suggest
additional objectives for consideration
that address critical public health issues
within existing Healthy People 2020
Topic Areas. All proposed new
objectives must meet all of the objective
selection criteria (see below).
Written comments will be accepted at
https://healthypeople.gov/2020/about/
publicComment.aspx during a threeweek public comment period beginning
in November 2013. The public will also
be able to submit written comments via
mail, fax, and email (see contact
information above). Comments received
in response to this notice will be
reviewed and considered by the Topic
Area workgroups, Federal Interagency
Workgroup on Healthy People 2020, and
other Healthy People 2020 stakeholders.
Objective Selection Criteria
The following nine criteria should be
taken into consideration when
commenting on the proposed or
suggesting additional objectives.
1. The result to be achieved should be
important and understandable to a
broad audience and support the Healthy
People 2020 goals.
2. Objectives should be prevention
oriented and should address health
improvements that can be achieved
through population-based and
individual actions, and systems-based,
environmental, health-service, or policy
interventions.
3. Objectives should drive actions that
will work toward the achievement of the
proposed targets (defined as quantitative
values to be achieved by the year 2020).
4. Objectives should be useful and
reflect issues of national importance.
Federal agencies, states, localities, nongovernmental organizations, and the
public and private sectors should be
able to use objectives to target efforts in
schools, communities, work sites, health
practices, and other environments.
5. Objectives should be measurable
and should address a range of issues,
such as: behavior and health outcomes;
availability of, access to, and content of
behavioral and health service
interventions; socio-environmental
conditions; and community capacity—
directed toward improving health
outcomes and quality of life across the
life span. (Community capacity is
defined as the ability of a community to
plan, implement, and evaluate health
strategies.)
6. Continuity and comparability of
measured phenomena from year to year
are important, thus, when appropriate,
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
retention of objectives from previous
Healthy People iterations is encouraged.
However, in instances where objectives
and/or measures have proven ill-suited
to the purpose or are inadequate, new
improved objectives should be
developed. Whether or not an objective
has met its target in a previous Healthy
People iteration should not be the sole
basis for retaining or archiving an
objective.
7. The objectives should be supported
by the best available scientific evidence.
The objective selection and review
processes should be flexible enough to
allow revisions to objectives in order to
reflect major updates or new knowledge.
8. Objectives should address
population disparities. These include
populations categorized by race/
ethnicity, socioeconomic status, gender,
disability status, sexual orientation, and
geographic location. For particular
health issues, additional special
populations should be addressed, based
on an examination of the available
evidence on vulnerability, health status,
and disparate care.
9. Healthy People 2020, like past
versions, is heavily data driven. Valid,
reliable, nationally representative data
and data systems should be used for
Healthy People 2020 objectives. Each
objective must have (1) A data source,
or potential data source, identified, (2)
baseline data and (3) assurance of at
least one additional data point
throughout the decade.
Dated: November 7, 2013.
Don Wright,
Deputy Assistant Secretary for Health, Office
of Disease Prevention and Health Promotion.
[FR Doc. 2013–27126 Filed 11–12–13; 8:45 am]
BILLING CODE 4150–32–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–13–13ZZ]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC 20503 or by fax to (202) 395–5806.
E:\FR\FM\13NON1.SGM
13NON1
68075
Federal Register / Vol. 78, No. 219 / Wednesday, November 13, 2013 / Notices
Written comments should be received
within 30 days of this notice.
Proposed Project
Evaluation of the SAMHSA PDMP
Electronic Health Record (EHR)
Integration and Interoperability
Expansion Program—New—National
Center for Injury Prevention and Control
(NCIPC), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
In 2009, drug overdose deaths became
the leading cause of injury death in the
United States (U.S.), exceeding motor
vehicle traffic crash deaths for the first
time, a trend that continued in 2010.
Prescription drugs, particularly opioid
pain relievers, have been identified as
the main driver of this increase. The
number of overdose deaths per year
involving opioid pain relievers
increased more than four-fold from 1999
to 2010 (from 4,030 to 16,651),
outnumbering overdose deaths
involving all illicit drugs combined.
Morbidity associated with opioid pain
reliever abuse increased in parallel. The
rate of emergency department visits
associated with the misuse or abuse use
of opioid pain relievers increased 153%
from 2004 to 2011, while rates for illicit
drugs remained largely stable.
This project involves an evaluation of
the Substance Abuse and Mental Health
Services (SAMHSA) Prescription Drug
Monitoring Program (PDMP) Electronic
Health Record (EHR) Integration and
Interoperability Expansion Program
(PEHRIIE) which has funded projects in
nine states via cooperative agreements.
Under these cooperative agreements,
the Centers for Disease Control and
Prevention (CDC) is responsible for
conducting a comprehensive process
and outcomes evaluation of the PEHRIIE
program. The primary goals of the
qualitative evaluation component of this
work are:
1. To understand the processes,
challenges, and successes in
implementing and sustaining
integration of PDMP data with Health
Information Technology (HIT) systems
and interoperability of PDMP systems
across states; and
2. To understand the experiences of
clinical end users with the systems
being upgraded under the PEHRIIE
program and to capture their
recommendations, if any, for how the
goals of the PEHRIIE could have been
better accomplished.
In order to achieve these evaluation
goals, CDC requests OMB approval for
24 months in order for the CDC
evaluation team to conduct qualitative
interviews with those individuals
involved in the planning and
implementation of the PEHRIIE projects
(i.e., key project staff and stakeholders)
as well as with the clinical end users
(i.e., prescribers and pharmacists) of the
PDMPs in the states where these
projects are taking place. Through this
evaluation, CDC will better understand
the impact of PDMP integration and
interoperability in the funded states.
The total annual estimated burden
hours for the planned qualitative
information collection are 119 hours.
Total burden time includes the time to
conduct interviews with key project
staff/stakeholders and clinical end
users, and the time spent by recruiters
at the PEHRIIE implementation sites to
identify potential clinical end user
interviewees.
Staff/stakeholder interviews will be
conducted with key project staff
members/stakeholders across the nine
PEHRIIE-funded states. Interviews will
also be conducted with key project staff/
stakeholders representing companies
working with multiples states involved
in the PEHRIIE program.
End user interviews will be
conducted at implementation sites
distributed across all nine PEHRIIE
states. The CDC will work with one
recruiter per implementation site to
complete these tasks.
There are no costs to respondents
other than their time. The total
estimated annual burden hours are 119
hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Form name
Key Project Staff/Stakeholders
Key Project Staff/Stakeholders Interview
Guide
End Users Interview Guide
N/A .................................................................
Clinical End Users
Clinical End User Recruiters
Kimberly S. Lane,
Deputy Director, Office of Science Integrity,
Office of the Associate Director for Science,
Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2013–27083 Filed 11–12–13; 8:45 am]
BILLING CODE 4163–18–P
sroberts on DSK5SPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Mar<15>2010
17:14 Nov 12, 2013
Number of
respondents
Jkt 232001
Number of
responses per
respondent
Average
burden
per
response
(in hrs)
53
1
45/60
59
20
1
1
1
1
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Date: December 3, 2013.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Rebecca C Steiner, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6149, MSC 9608,
Bethesda, MD 20892–9608, 301–443–4525,
steinerr@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel
Review of Eating Disorders Dimensional
Research (R01).
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
E:\FR\FM\13NON1.SGM
13NON1
]]>Agencies
[Federal Register Volume 78, Number 219 (Wednesday, November 13, 2013)]
[Notices]
[Pages 68074-68075]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27083]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30 Day-13-13ZZ]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
(404) 639-7570 or send an email to omb@cdc.gov. Send written comments
to CDC Desk Officer, Office of Management and Budget, Washington, DC
20503 or by fax to (202) 395-5806.
[[Page 68075]]
Written comments should be received within 30 days of this notice.
Proposed Project
Evaluation of the SAMHSA PDMP Electronic Health Record (EHR)
Integration and Interoperability Expansion Program--New--National
Center for Injury Prevention and Control (NCIPC), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
In 2009, drug overdose deaths became the leading cause of injury
death in the United States (U.S.), exceeding motor vehicle traffic
crash deaths for the first time, a trend that continued in 2010.
Prescription drugs, particularly opioid pain relievers, have been
identified as the main driver of this increase. The number of overdose
deaths per year involving opioid pain relievers increased more than
four-fold from 1999 to 2010 (from 4,030 to 16,651), outnumbering
overdose deaths involving all illicit drugs combined. Morbidity
associated with opioid pain reliever abuse increased in parallel. The
rate of emergency department visits associated with the misuse or abuse
use of opioid pain relievers increased 153% from 2004 to 2011, while
rates for illicit drugs remained largely stable.
This project involves an evaluation of the Substance Abuse and
Mental Health Services (SAMHSA) Prescription Drug Monitoring Program
(PDMP) Electronic Health Record (EHR) Integration and Interoperability
Expansion Program (PEHRIIE) which has funded projects in nine states
via cooperative agreements.
Under these cooperative agreements, the Centers for Disease Control
and Prevention (CDC) is responsible for conducting a comprehensive
process and outcomes evaluation of the PEHRIIE program. The primary
goals of the qualitative evaluation component of this work are:
1. To understand the processes, challenges, and successes in
implementing and sustaining integration of PDMP data with Health
Information Technology (HIT) systems and interoperability of PDMP
systems across states; and
2. To understand the experiences of clinical end users with the
systems being upgraded under the PEHRIIE program and to capture their
recommendations, if any, for how the goals of the PEHRIIE could have
been better accomplished.
In order to achieve these evaluation goals, CDC requests OMB
approval for 24 months in order for the CDC evaluation team to conduct
qualitative interviews with those individuals involved in the planning
and implementation of the PEHRIIE projects (i.e., key project staff and
stakeholders) as well as with the clinical end users (i.e., prescribers
and pharmacists) of the PDMPs in the states where these projects are
taking place. Through this evaluation, CDC will better understand the
impact of PDMP integration and interoperability in the funded states.
The total annual estimated burden hours for the planned qualitative
information collection are 119 hours. Total burden time includes the
time to conduct interviews with key project staff/stakeholders and
clinical end users, and the time spent by recruiters at the PEHRIIE
implementation sites to identify potential clinical end user
interviewees.
Staff/stakeholder interviews will be conducted with key project
staff members/stakeholders across the nine PEHRIIE-funded states.
Interviews will also be conducted with key project staff/stakeholders
representing companies working with multiples states involved in the
PEHRIIE program.
End user interviews will be conducted at implementation sites
distributed across all nine PEHRIIE states. The CDC will work with one
recruiter per implementation site to complete these tasks.
There are no costs to respondents other than their time. The total
estimated annual burden hours are 119 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hrs)
----------------------------------------------------------------------------------------------------------------
Key Project Staff/Stakeholders Key Project Staff/ 53 1 45/60
Stakeholders Interview
Guide
Clinical End Users End Users Interview 59 1 1
Guide
Clinical End User Recruiters N/A..................... 20 1 1
----------------------------------------------------------------------------------------------------------------
Kimberly S. Lane,
Deputy Director, Office of Science Integrity, Office of the Associate
Director for Science, Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2013-27083 Filed 11-12-13; 8:45 am]
BILLING CODE 4163-18-P
